OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

Subrata Ghosh

doi:10.1093/ecco-jcc/jjac190.0039

OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

Subrata Ghosh

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of Crohn's and Colitis
DOIs	https://doi.org/10.1093/ecco-jcc/jjac190.0039
Publication status	Published - 2023

Keywords

Medicine
Ustekinumab
Adverse effect
Safety profile
Nausea
Inflammatory bowel disease
Internal medicine
Pediatrics
Surgery
Disease
Infliximab

Access to Document

10.1093/ecco-jcc/jjac190.0039

https://openalex.org/W4318539915Licence: CC BY-NC-ND

Cite this

@article{aaaddf95e9da4ff68a3464906c041340,

title = "OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC",

keywords = "Medicine, Ustekinumab, Adverse effect, Safety profile, Nausea, Inflammatory bowel disease, Internal medicine, Pediatrics, Surgery, Disease, Infliximab",

author = "Subrata Ghosh",

year = "2023",

doi = "10.1093/ecco-jcc/jjac190.0039",

language = "English",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

AU - Ghosh, Subrata

PY - 2023

Y1 - 2023

KW - Medicine

KW - Ustekinumab

KW - Adverse effect

KW - Safety profile

KW - Nausea

KW - Inflammatory bowel disease

KW - Internal medicine

KW - Pediatrics

KW - Surgery

KW - Disease

KW - Infliximab

U2 - 10.1093/ecco-jcc/jjac190.0039

DO - 10.1093/ecco-jcc/jjac190.0039

M3 - Article

SN - 1873-9946

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

ER -